troglitazone has been researched along with Focal Segmental Glomerulosclerosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ma, LJ | 1 |
Marcantoni, C | 1 |
Linton, MF | 1 |
Fazio, S | 1 |
Fogo, AB | 1 |
1 other study available for troglitazone and Focal Segmental Glomerulosclerosis
Article | Year |
---|---|
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Topics: Animals; Antihypertensive Agents; Base Sequence; Chromans; Disease Models, Animal; DNA Primers; Glom | 2001 |